About Sammy Elmariah, MD, MPH

Dr. Sammy Elmariah is an interventional cardiologist, structural heart and valve disease specialist, as well as a clinical and translational investigator at the Massachusetts General Hospital seeking to improve clinical outcomes for patients with valvular heart disease (VHD). He is an Assistant Professor of Medicine at the Harvard Medical School and serves as the Director of Interventional Cardiology Research.Dr. Elmariah graduated from the University of Pennsylvania School of Medicine and completed his internal medicine residency training at the Hospital of the University of Pennsylvania. Dr. Elmariah completed his fellowship in cardiovascular medicine at the Mount Sinai Hospital in New York and a Masters in Public Health degree at the Harvard School of Public Health. Dr. Elmariah completed further fellowship training in interventional cardiology and structural heart disease at the Massachusetts General Hospital.His clinical interest is in the management of valvular heart disease and in the transcatheter repair and replacement of aortic, mitral, and tricuspid valves. Dr. Elmariah is involved in a myriad of ongoing clinical investigations seeking to advance our understanding of the heart's response to aortic stenosis and also to identify informative biomarkers to help guide the timing of valve replacement procedures. In addition, Dr. Elmariah leads several ongoing clinical trials at MGH investigating novel devices for the management of mitral and tricuspid regurgitation and aortic stenosis. His research is funded by the National Institutes of Health, the American Heart Association, the US Department of Defense, and several industry partners.

Clinical Interests:



Mass General Heart Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-6120
Fax: 617-726-9839

Medical Education

  • MPH, Harvard T. H Chan School of Public Health
  • MD, University of Pennsylvania Medical Ctr.
  • Residency, Hospital of the University of Pennsylvania
  • Residency, Lankenau Hospital
  • Fellowship, Massachusetts General Hospital
  • Fellowship, Mount Sinai Hospital Medical Center

American Board Certifications

  • Cardiovascular Disease, American Board of Internal Medicine
  • Interventional Cardiology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Elmariah's research focuses on the prediction and optimization of clinical outcomes of patients with aortic stenosis and after transcatheter aortic valve replacement. Aortic valve stenosis is a disorder predominantly affecting the elderly and characterized by severe narrowing of the aortic valve, the doorway through which blood exits the heart. Aortic stenosis ultimately leads to heart failure and death. Surgical or transcatheter replacement of the valve cures the valve obstruction, but valve replacement is routinely reserved until compensatory mechanisms within the heart have failed. For many patients, this point is too late. Despite valve replacement, damage to the heart muscle may be permanent, resulting in persistent symptoms and increased risk for death. Methods capable of identifying early stages of irreversible heart injury due to aortic valve stenosis are needed in order to help optimize the timing of surgery.

The long-term goal of Dr. Elmariah's work is to identify novel blood markers using novel proteomic and metabolomic profiling techniques that predict heart recovery after valve surgery. Dr. Elmariah anticipates that such measures will help physicians optimize the timing of aortic valve replacement in order to maximize the likelihood that surgery will improve their patients’ symptoms and prolong their lives. Additionally, the type of heart injury that occurs with aortic stenosis also occurs with high blood pressure, diabetes, and several other diseases. Findings from his research have the potential to improve the quality of care for many of these diseases as well.


  • Select Publications:

    • Elmariah S, Farrell LA, Daher M, et al. Metabolite profiles predict acute kidney injury and mortality in patients undergoing transcatheter aortic valve replacement. J Am Heart Assoc. 2016;5(3). 
    • Mauri L, Elmariah S, Yeh RW, et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016;37(4):378-85.
    • Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: final 5-year results of the EVEREST II study. J Am Coll Cardiol. 2015;66(25):2844-54.
    • Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015;385(9970):792-8.
    • Passeri JJ, Elmariah S, Xu K, et al. Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low ejection fraction. 2014;101(6):463-71.
    • Elmariah S, Furlan AJ, Reisman M, et al. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I trial. JACC Cardiovasc Interv. 2014;7:913-20.
    • Elmariah S, Palacios IF, McAndrew T, et al. Outcomes of transcatheter and surgical aortic valve replacement in high-risk patients with aortic stenosis and left ventricular dysfunction: Results from the PARTNER trial (Cohort A). Circ Cardiovasc Interv. 2013;6(6):604-14.

Reviews: Comments and Ratings